The evaluation of the clinical efficacy of Prodexyn vaginal suppositories in the treatment of recurrent bacterial vaginosis

<p><strong>Background</strong>. Bacterial vaginosis (BV) is the most common vaginal infection among women of reproductive age and is associated with an increased risk of sexually transmitted infections and pregnancy complications. First-line antimicrobial treatments are often accompanied by recurrences due to bacterial resistance, biofilm formation, and other factors.<br><strong>Objective of the study</strong>: to evaluate the clinical efficacy, impact on vaginal microbiota, and safety profile of a combination product containing octenidine dihydrochloride and dexpanthenol<br>(Prodexyn) in the treatment of recurrent BV.<br><strong>Materials and methods</strong>. A prospective study conducted in 2024 and included 192 patients aged 18–36 years with recurrent BV. The participants were divided into two groups: group I – 74 women treated with suppositories based on octenidine dihydrochloride and dexpanthenol, group II – 118 women treated with alternative vaginal antimicrobial drugs (subgroups receiving ternidazole, metronidazole, tinidazole). Efficacy was assessed by symptom resolution, analysis of vaginal microbiota using Hay-Ison criteria, and quality of life using the SF-36 questionnaire.<br><strong>Results</strong>. Group I, treated with octenidine dihydrochloride and dexpanthenol (Prodexyn), demonstrated a higher symptom resolution rate (91.2%) compared to group II (76.3%, p < 0.05). Follow-up PCR analyses confirmed the restoration of normal vaginal biocenosis in 87.5% of patients in group I compared to women in group II: in the ternidazole subgroup, the hazard ratio (HR) was 1.37, 95% confidence interval (CI) was 1.05–1.78 (p = 0.019), in the metronidazole subgroup HR = 1.63, 95% CI = 1.14–2.33 (p = 0.007), in the tinidazole subgroup HR = 1.62, 95% CI = 1.12–2.35 (p = 0.009). The safety profile was favorable, with minimal adverse effects reported.<br><strong>Conclusions</strong>. The combination product containing octenidine dihydrochloride and dexpanthenol (Prodexyn) demonstrates high clinical efficacy, promotes the restoration of normal vaginal microbiota, and has a favorable safety profile. These findings support its use as an effective approach in the treatment of recurrent bacterial vaginosis.</p>